BioDelivery Sciences International (NASDAQ: BDSI) and Opko Health (NASDAQ:OPK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares BioDelivery Sciences International and Opko Health’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
BioDelivery Sciences International $15.55 million 8.44 -$67.13 million ($0.19) -12.37
Opko Health $1.22 billion 2.29 -$25.08 million ($0.19) -26.37

Opko Health has higher revenue and earnings than BioDelivery Sciences International. Opko Health is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for BioDelivery Sciences International and Opko Health, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioDelivery Sciences International 0 1 5 0 2.83
Opko Health 0 2 6 0 2.75

BioDelivery Sciences International presently has a consensus price target of $4.50, indicating a potential upside of 91.49%. Opko Health has a consensus price target of $14.81, indicating a potential upside of 195.66%. Given Opko Health’s higher possible upside, analysts clearly believe Opko Health is more favorable than BioDelivery Sciences International.

Risk and Volatility

BioDelivery Sciences International has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.

Insider & Institutional Ownership

43.9% of BioDelivery Sciences International shares are held by institutional investors. Comparatively, 22.3% of Opko Health shares are held by institutional investors. 9.0% of BioDelivery Sciences International shares are held by insiders. Comparatively, 40.2% of Opko Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares BioDelivery Sciences International and Opko Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioDelivery Sciences International 10.40% 33.83% 6.43%
Opko Health -9.45% -5.17% -3.94%

Summary

Opko Health beats BioDelivery Sciences International on 7 of the 13 factors compared between the two stocks.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Opko Health Company Profile

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.